REGistry of Long-term AnTithrombotic TherApy-1 (REGATTA-1)
Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes
Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Listed as NCT04347200, this observational or N/A phase trial focuses on Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)) and Peripheral Artery Disease and remains actively recruiting participants. Sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation, it has been updated 9 times since 2015, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Study Description(click to expand)The register is a Russian prospective single-center observational study of patients who have indications for long-term antithrombotic therapy in connection with chronic coronary syndromes
The register is a Russian prospective single-center observational study of patients who have indications for long-term antithrombotic therapy in connection with chronic coronary syndromes
Status Flow
Change History
9 versions recorded-
May 4, 2026 — Present [daily]
Recruiting
-
Sep 2025 — May 2026 [monthly]
Recruiting
-
Apr 2025 — Sep 2025 [monthly]
Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 4 earlier versions
-
Dec 2021 — Jul 2024 [monthly]
Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
May 2020 — Nov 2020 [monthly]
Recruiting
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with chronic coronary syndromes
Contact Information
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
For direct contact, visit the study record on ClinicalTrials.gov .